Plasma Galectin-3 and H-FABP correlate with poor physical performance in patients with congestive heart failure

Firdos Ahmad1,2, Asima Karim1, Javaidullah Khan3

  • 1Basic Medical Sciences, College of Medicine, University of Sharjah, Sharjah 27272, United Arab Emirates.

Insights

Congestive heart failure (CHF) significantly impairs physical function. Heart failure markers galectin-3 and heart-specific fatty acid binding protein (H-FABP) correlate with reduced physical performance, suggesting their role as biomarkers for disability in CHF patients.

Area of Science:

  • Cardiology
  • Biomarkers
  • Physical Performance

Background:

  • Heart failure (HF) is linked to reduced physical capacity.
  • The relationship between established HF markers and physical performance in congestive HF (CHF) patients requires further investigation.

Purpose of the Study:

  • To assess correlations between cardiac function markers (LVESD, LVEF) and physical performance (SPPB, GS, HGS) in CHF patients.
  • To investigate the association of plasma HF markers (galectin-3, H-FABP) with HF severity and physical performance.

Main Methods:

  • Eighty CHF patients and 59 healthy controls were evaluated.
  • Measurements included left ventricular end-systolic dimension (LVESD), ejection fraction (LVEF), short physical performance battery (SPPB), gait speed (GS), handgrip strength (HGS), plasma galectin-3, H-FABP, zonulin, and C-reactive protein (CRP).

Main Results:

  • CHF patients exhibited higher LVESD, lower LVEF, and reduced SPPB, GS, and HGS compared to controls.
  • Elevated galectin-3 and H-FABP levels were observed in CHF patients, correlating inversely with SPPB and HGS.
  • Galectin-3 and H-FABP levels also correlated with CRP, indicating a link to systemic inflammation.

Conclusions:

  • Congestive heart failure significantly compromises physical performance.
  • Galectin-3 and H-FABP show potential as biomarkers for physical disability in CHF.
  • Systemic inflammation may contribute to the physical impairments observed in CHF patients.

Related Concept Videos

Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
31
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.7K
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
134
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
20
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
21
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19